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A B S T R A C T
Nucleic acid testing (NAT) for pathogenic ﬁloviruses plays a key role in surveillance and to control the spread of
infection. As they share clinical features with other pathogens, the initial spread of these viruses can be mis-
diagnosed. Tests that can identify a pathogen in the initial stages of infection are essential to control outbreaks.
Since the Ebola virus disease (EVD) outbreak in 2014–2016 several tests have been developed that are faster
than previous tests and more suited for ﬁeld use. Furthermore, the ability to test for a range of pathogens
simultaneously has been expanded to improve clinical pathway management of febrile syndromes. This review
provides an overview of these novel diagnostic tests.
1. Introduction
The Ebolaviruses are a group of closely related viruses in the ﬁlo-
viridae family. Filoviruses have negative-sense RNA genomes protected
by the nucleocapsid protein (Fig. 1A). There are ﬁve distinct Ebolavirus
species; Bundibugyo (BDBV), Reston (RESTV), Sudan (SUDV), Taï forest
(TAFV, formerly Cote d’Ivoire Ebolavirus) and Zaire (EBOV). All ﬁve
members can cause infections in humans albeit with a wide spectrum of
disease severity. The Zaire and Sudan species cause Ebolavirus Disease
(EVD) with a fatality rate ranging from 40 to 90% [1]. These viruses,
along with other more distantly related ﬁloviruses, Marburg virus
(MARV) and Ravn virus (RAVV), are biosafety level 4 agents associated
with high fatality rates and an absence of eﬀective treatments [2].
The ﬁrst documented Ebolavirus, and prototypic virus for the group,
EBOV, was isolated in an outbreak of a haemorrhagic fever in Africa
within the democratic Republic of Congo (formerly Zaire) in 1976 [3],
nine years after MARV had been discovered in a laboratory-centred
outbreak in Marburg, Germany. Both TAFV and RESTV are somewhat
unusual within the Ebolavirus group as ﬁrstly; they do not appear to
cause severe pathology in humans, (in non-human primates, infections
are highly pathogenic) and secondly the sources were outside the
central African continental region associated with ﬁlovirus outbreaks.
Filoviruses are considered to be zoonotic; there is evidence that bats
are likely to be an animal reservoir for a number of viruses. Bats can
harbour Ebolaviruses and Marburg virus, which replicate without
causing symptoms of EVD [4]; ﬁlovirus RNA has been isolated from 3
species of bat [5,6] and more species have been shown to have anti-
bodies against Ebolavirus [7–11]. Evidence suggests that contact be-
tween humans and fruit bats are the cause of at least one outbreak [12].
Furthermore, experiments have shown that pigs infected with EBOV
can transmit virus to non-human primates kept in the same room but
with no physical contact [13].
In March 2014 an outbreak of the EBOV began in western Africa.
This was the largest outbreak recorded and spanned several countries in
the region. Initially there were relatively few cases but they rapidly
increased as transmission started to occur in densely populated areas. In
2014 the World Health Organisation (WHO) declared the epidemic as a
Public Health Emergency of International Concern (PHEIC) [14]. The
PHEIC was declared over, in March 2016 after the three countries, that
were the main focus of the international response, completed 42 days
with no newly reported cases and an additional 90 days of enhanced
surveillance [15]. During the 2-year outbreak, there were more than
28,600 suspected, possible or conﬁrmed cases of which 11,310 were
fatal (∼40% case fatality rate) [16]. This epidemic highlighted the
need for rapid diagnostics and epidemiology for disease tracking and
containment. The unprecedented scale of the EVD outbreak spurred
research into the ﬁlovirus ﬁeld with the swift deployment of experi-
mental vaccines, for phase I/II [17–27] and III trials [28], and devel-
opment of diagnostics suited for low resource and in-ﬁeld environ-
ments.
Future development of diagnostics focusing on rapid, sensitive and
speciﬁc assays will be especially helpful in triage, as the symptoms of
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early EVD overlap with several other infections found in equatorial
regions (e.g. malaria). Early isolation of EBOV infected individuals
decreases the chance of perpetuating infections by breaking transmis-
sion chains. In this review, current and proposed methods and
techniques for Ebolavirus diagnosis using nucleic acids (see Table 1 for
advantages and disadvantages) will be described. Other technologies
are not covered (e.g. ELISA, cell culture, EM).
Fig. 1. Structure and ﬁlovirus divergence. A. Schematic of a ﬁlovirus particle. Nucleotide sequence phylogenetic trees, prepared with NCBI genomics workbench
using nearest neighbour joining, showing the main targets GP (B) and NP (C) for ﬁlovirus NATs. The divergence in sequence requires speciﬁc primers for each
species/subspecies. Scale bar denotes nucleotide substitutions per site.
Table 1
Advantages and disadvantages of NATs.
Advantages Disadvantages
The ability to diagnose an infection prior to the adaptive immune response Small window of diagnosis (viraemia ﬁrst detectable between 3 and 10 days of initial infection)
compared to antigen and antibody tests
A high speciﬁcity and multiplex compatibility RNA is susceptible to rapid degradation by RNases
Greater sensitivity; most NATs amplify an initial sample Cannot identify past infections, unlike antibody tests
Reduced operator handling (giving enhanced safety) PCR product contamination risk due to ampliﬁcation of initial sample
No requirement for category 4 level cell culture Pathogen genetic drift could result in decreased sensitivity (If using DNA primers/capture probes)
Speed (with the exception of antigen RDTs)
Deﬁnitive of virus presence; in the absence of a viral genome, there is no ampliﬁcation
D.J. Clark et al. Journal of Clinical Virology 103 (2018) 27–36
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2. Sample collection and storage
For most of the diagnostic methods used to determine the presence
of virus (or evidence of contact with Ebolavirus and closely related ﬁ-
loviruses) a blood sample is required. WHO recommendations for ve-
nepuncture, in cases of suspected EBOV or MARV, state that blood
should be collected into EDTA tubes with a minimum volume of 5ml.
For blood collection guidelines please refer to: http://www.who.int/
csr/resources/publications/ebola/blood-collect/en/. The WHO guide-
lines further state that blood samples can be stored for up to 24 h at
room temperature, or at 0–5° C for up to a week. For periods of longer
than a week, the sample should be stored at −20 or −70° C (avoiding
freeze thaw cycles) [29].
Oral swab collection has been tested in a guinea pig model of EVD
[30]. The authors considered the test to be poor for samples collected
ante mortem but excellent for post mortem specimens. Oral swab col-
lection during the 2014–2016 west Africa outbreak has also been ex-
amined for post mortem surveillance [31]. The same study tested ﬁnger-
stick sampling with pipette or swab collection, which in ﬁeld point-of-
care applications may be more feasible than venepuncture.
3. Sample preparation
As with all PCR-based assays, the purity of the input template is
important for standardising tests. Due to inhibitors found in blood
(reviewed in [32]) most diagnostic tests require the genome of a ﬁ-
lovirus to be isolated from a sample; for example, to obtain a vir-
aemia, RNA needs to be isolated from the blood plasma. One fre-
quently used method utilises acid guanidinium thiocyanate-phenol-
chloroform to separate a sample into an aqueous (containing RNA)
and organic phase (containing DNA). This also has the important
advantage of inactivating infectious material as proteins are dena-
tured, although for complete inactivation of Ebolavirus, a secondary
ethanol step appears to be necessary [33]. However, this method can
be impracticable as it is both time consuming for an operator and
uses harmful chemicals.
Commercial RNA extraction kits, many of which are based on
chaotropic chemical (e.g. guanidine-isothiocyanate) extraction, use
centrifugation (or vacuum) of columns containing glass ﬁber ﬁlters to
isolate RNA, allowing batch processing. Other kits use beads, with high
nucleic acid adherence, followed by magnetic separation. Most kits can
Table 2
RT-PCR papers; targets, primers and sensitivity for ﬁlovirus detection.
Paper Target gene/sequence Primers Sensitivity*
Leroy [69] Polymerase, L Zaire F 5′- ATCGGAATTTTCTTTCTCATTGAAAGA-3′ 100% (30/30) (95% CI 88.4–100)**
Zaire R 5′- ATGTGGTGGATTATAATAATCACTGACATGCAT-3′






Park [71] NP BDBV F GCAGAAATATGCTGAATCTCGTGAAC 5 fg/μL
BDBV R ATCATCCTCGTCCTCAAGGTCAAAA
RESTV F CCAACAATATGCTGAGTCCAGAGAA 5 fg/μL
RESTV R
CATCCTCATGATCGTCAAGATCG
SUDV F ACACGTGAGTTGGACAACCTT 5 fg/μL
SUDV R GTCATCGTCGTCGTCCAAATTGAA
TEBOV F AATCTCGCGAGCTTGACCAT 5 fg/μL
TEBOV R CTCGTCACCATCTTCAAGGTCAAA
EBOV F CGAACTTGACCATCTTGGACTTG 5 fg/μL
EBOV R TCCTCGTCGTCCTCGTCTAGAT
MARV F AGGCGACATGAACATCAGGAAATT 5 fg/μL
MARV R TCGTCCTCATTCAGCAGTGCAAAT
RAVV F GCGACATGAACACCAGGAAATTC 500 fg/μL
RAVV R ATTTTCAAGAGTATCCTCGTCTTCG
Ogawa 2011[72] NP MARV FiloNP-Fm TGGCTTACYACAGGYCACATGAAAGT 10−3
MARV FiloNP-Rm GTGTGTGATTTCAGTTTTYTGGAGGTGGAA FFU/reaction***




Bergqvist 2015[73] (NB Multiplex) L EV F1 Biotin CGTTTIAAIACCMIWCTSATTGC
EV F2 Biotin CGATTCAACACAACTCTAATCTC
EV F3 Biotin CGATTTAATACTTTACTGATTGC
EV F4 Biotin AGGTTIAATACATCACTGATTGC
EV R Phosphor GGRTGSCCCCARTGYTTTTGVA
EBOV P C12-NH2 GCATAGACACAATCTTAAAATTG 1500 copies/mL
SUDV P C12-NH2 GAGATTGAATATCATCTACCAGT 150 copies/mL
TAFV P C12-NH2 GGTCAGACACTGTTTCTGGTA 150k copies/mL
GP MV F Biotin ACACYYYCAARHRCAACYTCAGYAC
MV R Phosphor TCAAAATCAATYKSAGYAYTTATTAACCCRTC
RAVV P C12-NH2 GCTAGTTCACGTTGTGTATCATT
MARV OZOLIN P C12eNH2 CCAACACACAAAGCATGGCCACTG
MARV MUSOKE P GATTGTGCTCTGTGTGTTGTC
MARV LEIDEN/POPP P GTGGCTGTGCTCTGTGTGTCGTA
* where available.
** where antigen detection used as standard (from 26 symptomatic patients, 3 convalescent and 1 healthy).
*** FFU: Focus forming unit.
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concentrate nucleic acids which has the potential of improving the
sensitivity of downstream assays.
Due to the sensitivity of RNA to RNases, care must be taken to
minimize degradation of extracted samples prior to reverse transcrip-
tion. However, there is now a move towards using all-in-one RNA iso-
lation and reaction devices, as this minimizes the exposure of sample to
RNases and of staﬀ to potentially infectious material and reduces op-
erator dependent variation allowing for more standardized tests.
4. Diagnostics
All members of the ﬁloviridae have negative-sense RNA genomes
and therefore require a reverse transcription step before polymerase
chain reaction (PCR) can be performed. There are three main reverse
transcriptase PCR techniques, as described below.
4.1. RT-PCR
There are two main methods of reverse transcriptase PCR; one step
and two step. In one step RT-PCR, the sample and all required reagents
are within one reaction chamber/tube and an initial reverse tran-
scription step is directly followed by PCR cycling. cDNA libraries of
total RNA in a sample can be prepared using random primers, or spe-
ciﬁc pathogen primers can be used; thereby only generating cDNA of a
particular pathogen.
In two step RT-PCR, the reverse transcription and PCR are per-
formed separately; the ﬁrst to generate cDNA and the second for PCR,
following the transfer of template cDNA to another chamber. With a
cDNA library of total RNA, two step RT-PCR the resulting template can
be used in multiple separate assays but is time consuming and sensi-
tivity can be reduced due to splitting of the original sample.
In both one step and two step RT-PCR, the ﬁnal products are as-
sessed by agarose gel and is therefore more suited to qualitative diag-
nosis. The main advantage of this technique, compared to RT-qPCR, is
the cost; equipment to perform PCR and electrophoresis are relatively
inexpensive. However, it is not possible to multiplex within an assay;
while there is some RNA sequence conservation within a species of ﬁ-
lovirus there is far less between species (Fig. 1B and C). Published RT-
PCR assays are presented in Table 2.
4.2. RT-qPCR
This technique is very similar to RT-PCR but enables the sample to
be quantiﬁed against a known set of standards. It uses forward and
reverse primers and internal oligo probes with ﬂuorophores and
quenchers. qPCR machines measure ﬂuorescent signal from probe
break down, which occurs relative to ampliﬁcation, and can detect
multiple ﬂuorophores, allowing multiplexing within a single sample
(e.g. diﬀerentiating between Ebolavirus and Marburgvirus) [34]. Photon
multiplier tubes amplify ﬂuorescence signals, potentially increasing
sensitivity over RT-PCR. Furthermore, a large number of samples can
also be run at the same time as the standards; depending on the format
of the device, 96/384 wells. Examples of these machines include:
CFX96 (Biorad), Lightcycler (Roche), ABI 7000 series (Applied Biosys-
tems) and Rotor-Gene Q (Qiagen).
Published RT-qPCR assays for ﬁlovirus detection are presented in
Table 3. The benchmark that many of the newer tests are compared
against is the Trombley assay [35]. The targets described in this paper
are the nucleoprotein, glycoprotein and VP40 (matrix protein). Minor
groove binding (MGB) probes and standard Taqman™ probes were as-
sessed in this paper for a number of viral pathogens; MGB probes are
shorter than normal yet maintain speciﬁcity and increased primer
melting temperature (relative to similar length Taqman™ probes) by
adding a 3′ minor groove binding moiety that stabilises the probe-target
hybrid. The Trombley assay includes primers for a human gene (ribo-
nuclease P) as an endogenous control. Due to variation between the ﬁve
subtypes of Ebolavirus, separate primers and probes are required for
each. While this assay has high sensitivity for Zaire Ebolavirus (a lower
limit of detection (LLOD) of 0.0001 plaque forming unit per reaction) it
is expensive, time consuming and suited predominantly to well-
equipped diagnostics laboratories. During the 2014–2016 Ebolavirus a
number of RT-qPCR assays were authorised for emergency use (FDA
EUA) [36], presented in Table 4. Two platforms used during the epi-
demic (Biocartis Idylla and Cepheid GeneXpert) have sample-to-result
cartridges, whereas the others require sample preparation before the
RT-qPCR can be performed. This is of particular interest as using a
sample-to-result cartridge can reduce operator involvement, improving
safety, exposure to RNases and ease-of-use. The GeneXpert system was
used in Liberia during the 2014–2016 outbreak in a mobile laboratory
run by Liberian laboratory technicians who had been trained and sup-
ported by the Liberian Ministry of Health, WHO and other international
partners. Results from the laboratory were used for both clinical man-
agement and for determining discharge status of patients [37].
4.3. RT-LAMP
In contrast to standard RT-PCR, reverse transcription-loop mediated
isothermal ampliﬁcation (RT-LAMP) is conducted at one temperature
and therefore does not require high precision thermocyclers; this
technique is suited to low resource settings. Within a relatively short
time period, a very large pool of template can be produced (for in depth
methods see [38]). A by-product of the ampliﬁcation is magnesium
pyrophosphate, which can even be seen by eye, and is a useful diag-
nostic indicator where further analysis, by agarose gel for example, is
not available. While puriﬁed RNA is generally required for diagnosing
ﬁloviral infection, RT-LAMP is inﬂuenced to a lesser extent by PCR
inhibitors found in the blood and can therefore be used directly with
clinical samples [39,40]. As with RT-PCR, one of the main drawbacks of
this technique is the inability to multiplex. Published RT-LAMP assays
are presented in Table 5.
RT-LAMP was assessed during the 2014–2016 EBOV outbreak in
Guinea for surveillance and was directly compared with RT-qPCR [41].
In this study, buccal swabs (896) from cadavers and a small number of
serum samples (21), from individuals with high-risk of EVD (based on
contact tracing), were tested with both methods; none of the samples
were EBOV positive [41]. The assay had been developed prior to use in
Guinea [42,43] and then tested with 100 clinical samples from sus-
pected EVD cases from Guinea. Results were assessed by measuring the
turbidity (LA-200 device) of the RT-LAMP reaction or the level of
ﬂuorescence in the presence of an inter-chelating dye (Genie III device,
Optigene). Compared with RT-qPCR results, the assay was nearly as
sensitive (97.9% (95% CI: 88.7–100)) and positive results returned
within 25minutes [42]. Notably these assays used RNA isolated from
either buccal swabs or serum. Recently a test was developed that was
designed for direct whole blood use [44]. Whole blood is diluted 1:19 in
lysis buﬀer and ﬁltered (10 μm ﬁlter) into tubes containing lyophilised
RT-LAMP reagents; the authors state that the whole assay takes
40minutes.
4.4. Sequencing
Directly sequencing sample, and comparing to a database, allows
direct diagnosis of an infection [45]. As whole or partial fragments of
the pathogen are ampliﬁed (average read length mid-2015 was 5 kb
[46]) and sequenced, this can take longer than RT-qPCR. A major
strength of this technique is that, in addition to providing a diagnosis, it
allows tracking of pathogen spread, and monitoring for the develop-
ment of virulence and potential resistance. While sequencing generally
requires a well-resourced laboratory with both sequencing machinery
and computer analytics, portable systems have been developed. During
the 2014–2016 EBOV outbreak a sequencing device, MinION (Oxford
Nanopore Technologies) was used in Guinea for sequencing and
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analysis of 142 EBOV samples [45,46], demonstrating that in-ﬁeld use
of sequencing is feasible. For general surveillance of circulating viruses
in a region, next-generating sequencing has been proposed [47,48].
4.5. Novel and or secondary diagnostic nucleic acid methods
Novel ﬁlovirus nucleic acid-based diagnostics are presented in
Table 6. Of these, only one was granted Emergency Use during the
2014–2016 Ebolavirus outbreak was the FilmArray Biothreat E test
[49]. This test is similar to RT-qPCR in that it has a reverse transcription
step followed by a multiplexed PCR step. However, the products of the
initial PCR are distributed to an array of secondary PCRs which use
nested (internal) primers in combination with an interchelating ﬂuor-
escent dye. The ﬁnal products are measured using a ﬁlm array. The
assay itself is within a self-contained pouch in which the RNA template
is released by a combination of chemical and mechanical (bead beating)
means prior to RT and PCR. This assay has been tested both in the UK
[50] the USA [51] and in ﬁeld conditions in Sierra Leone [50] and
Guinea [52]. Aside from the Biothreat E test, those methods described
in Table 6 were not tested during the outbreak but show promise in
development of future diagnostics.
Utilization of far red ﬂuorophores has been examined with whole
Table 3
RT-qPCR papers, target primers/probe and sensitivity for ﬁlovirus detection.
Paper Target gene/sequence Primers Sensitivity
Towner (SEBOV)[70] NP Reverse transcription (and Forward primer) One step: 103/ml (1 copy/reaction), Two step: 105/ml
(100 copies/reaction)F 5′-GA AAGAGCGGCTGGCCAAA-3′.
R AACGATCTCCAACCTTGATCTTT
P GACCGAAGCCATCACGACTGCAT
Trombley [35] EBOV MGB, NP F565 5′-TCTGACATGGATTACCACAAGATC − 3′ 0.001 PFU/reaction
EBOV, GP R640 5′-GGATGACTCTTTGCCGAACAATC − 3′ p597S 6FAM-
AGGTCTGTCCGTTCAA-MGBNFQ
0.01 (584 copies)
F2000 5′ −TTTTCAATC CTCAAC CGTAAG GC − 3′
SUDV MGB, NP R2079 5′ − CAGTCC GGT CCCAGAATGTG − 3′ 0.1 PFU/reaction
p2058A 6FAM-CATGTGCCGCCCCATCGCTGC-TAMRA-3′
SUDV, GP F CAT GCA GAA CAA GGG CTC ATT C 0.1 PFU/reaction
R CTC ATC AAA CGG AAG ATC ACC ATC
P CAA CTT CCT GGC AAT
RESTV MGB, GP F AGG ATG GAG CTT TCT TCC TCT ATG 1.0 (34 copies)
R TAC CCC CTC AGC AAA ATT GAC T
RESTV, VP40 P CAG GCT GGC TTC AAC TGT AAT TTA CAG AGG 1 PFU/reaction
F TCA CCG CGA ACC CAA TG
R TCG CTT GTC ATG GTT GGA CTT
TEBOV MGB, GP P ACC ATT GCC C 1.0 (586 copies)
F CTA TGG TTA TCA CCC AGG ATT GTG
R GTA ACT ATC CTG CTT GTC CAT GTG
TEBOV, GP P TGC CAC TCT CCA GCC AGC CAT CCG 0.1 PFU/reaction
F CCC ATC TCC GCC CAC AA
R GAG TGG AAT CCT CTG AAA CCA ATT
BDBV, MGB P CGC AGG CGA AGA C 10−6 (RNA dilution)
F TGT ACA CAA AGT CTC AGG AAC TGG
R GTC ATA CAG GAA GAA GGC TCC TTC
panMARV MGB, GP P CCA TGC CCA GGA GGA CTC GCC TTT 0.1 (Ravn), 1.0 (Ci67), 10 (Musoke), 1.0 (Angola) PFU/reaction
panMARV, GP F ATG GAA ACC AAG GCG AAA CTG 0.1 (Ravn), 10 (Ci67), 1.0 Musoke), 10 (Angola) PFU/
reactionR TAC TTG TGG CAT TGG CTT GTC T
P CGG GTA GCC CCC AAC
F GAT TCC CCT TTG GAA GCA TCT
F2 GAT TCC CCT TTA GAG GCA TCC
R CAA CGT TCT TGG GAG GAA CAC
P ACG ATG GGC TTT CAG
F GAT TCC CCT TTG GAA GCA TCT
F2 GAT TCC CCT TTA GAG GCA TCC
R CAA CGT TCT TGG GAG GAA CAC
P AAA CGA TGG GCC TTC AGG GCAGG
P2 AAG CGA TGG GCT TTC AGG ACAGG
Drosten /Sanchez [74,75] L (MARV and EBOV) Filo A ATCGGAATTTTTCTTTCTCATT 5.3 copies/reaction (2647 copies/ml (1887 to 4964))
Filo B ATGTGGTGGGTTATAATAATCACTGACATG
Gibb [76] GP F TGGGCTGAAAAYTGCTACAATC LOD 8 PFU (10fg*)
R CTTTGTGMACATASCGGCAC
EBOV P CTACCAGCAGCGCCAGACGG
SUDV P TTACCCCCACCGCCGGATG 3 PFU (100fg*)
Weidmann [77] EBOV F ATGATGGAAGCTACGGCG LOD: 10 copies/reaction Comparable to MARV and EBOV





MARV F CAATTCCACCTTCAGAAAACTG LOD: 10 copies/reaction
MARV P CACACACAGTCAGACACTAGCCGTCCT
MARV R GCTAATTTTTCTCGTTTCTGGCT
MGB: Minor groove binding. NP: Nucleoprotein. GP: Glycoprotein. L: Polymerase.
* Puriﬁed RNA.
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blood samples to overcome signal inhibition of blood constituents. The
QuRapID system uses these dyes in addition to rapid freeze/thaw cycles
to isolate and then amplify viral RNA. The 20 kg stand-alone system has
been developed for ﬁeld use [53]. Two bead-based PCR assays were
developed to detect multiple RNA viruses from bat urine [54]. Brieﬂy, a
one-step RT-PCR is combined with primers with a 5′ tag (24 nt) and
biotinylated dCTP nucleotides. Fluorescently labelled microbeads with
an anti-tag sequence then bind to ampliﬁcation products. A Bio-plex
200 ﬂow cell instrument measures the bead and ampliﬁcation product.
This bead-based technology could be adapted for use in multiplex ﬁ-
lovirus diagnostics for humans.
5. Point-of-care diagnosis
A signiﬁcant goal for ﬁlovirus diagnostics is the development of
point-of care (POC) diagnosis. The ASSURED criteria set out by the
WHO for POC devices are:
Aﬀordable, Sensitive, Selective, User-friendly, Rapid, Equipment-
free, and Deliverable (to end users) [55]. After the start of the EVD
outbreak in 2014, a target product proﬁle for diagnostics for Ebolavirus
was proposed [56].
While there are rapid diagnostic tests based on an antibody response
to viral antigen(s), an early diagnosis of ﬁloviral infection is preferable,
ideally before the humoral response has developed, and nucleic acid
testing can do this. Studies in non-human primates have shown that
post exposure prophylaxis (PEP) using vaccines for ﬁloviruses can in-
crease rates of survival even 2 days post-exposure [57]. The recent
phase III trial of the VSV-ZEBOV vaccine indicates that this may be the
case for human infections with EBOV [28]. There is also evidence that
PEP with antibodies can be eﬀective in non-human primates [58,59]
and murine models [60]; notably a deﬁnitive diagnosis of a patient
would be required before administration of treatment. Evidence from
animal models indicate the earlier the administration of either vaccine
or antibodies the greater the survival odds.
Furthermore, in ﬁlovirus outbreak situations, POC devices could
play a key role in the triage of patients presenting to a clinic with fever.
Multiplexed devices could assess whether a patient has multiple infec-
tions; for example with a virus as well as malaria and thereby feed into
the clinical and therapeutic pathway [61]. A key aspect of POC devices
is that there is minimal sample handing and potentially pathogenic
material does not require transport to distant sites, thereby improving
the diagnostic turnaround time.
Two projects funded via the Innovative Medicine Initiative (IMI) are
attempting to address the need for novel near-patient ﬁlovirus diag-
nostics. A device that uses a laser based ultra-fast PCR is being devel-
oped by the FILODIAG consortium [62]. This technology utilises primer
coated nanoparticles that are rapidly heated by laser absorption and
then cool down immediately. This is faster than conventional thermo-
cyclers; the aim is to test for EBOV within 15min. A POC diagnostic
device is being developed by the Moﬁna consortium for Ebolaviruses
and Marburg virus detection. It is small, portable and will deliver re-
sults within 75min following skin prick blood sampling [63]. As such, it
will be well suited for in ﬁeld use during ﬁlovirus outbreaks.
6. Conclusions
Nucleic acid tests have the greatest potential for early detection of
ﬁlovirus infection. Their main strength is that only a small amount of
input material is required for both detection and typing (either by
speciﬁc primers/probes or sequencing). These tests can also be used in
live vaccine administration to assess viral replication.
While the main focus during an outbreak of ﬁloviral infections is
plasma viraemia, other sites of viral persistence have been identiﬁed
[64–68]. Assessing the ability of the described NATs when starting with
a diﬀerent clinical sample matrix is important. This is even more critical
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than puriﬁed RNA. The majority of the tests described in this review
have focused on ﬁloviral infections, yet the ideal test would incorporate
a number of likely pathogens for a region to allow discrimination be-
tween causes of fever. NATs that utilise multiplexing that are integrated
with novel POC platforms are eminently suited to this objective and,
ultimately, will revolutionise outbreak diagnostics.
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Novel NATs for detection of ﬁloviruses.
Test Notes
FilmArray Biothreat-E test [50–52,87] Whole blood or urine sample. Estimated LoD: 6×105 PFU/ml. FDA EUA.
QuRapID platform [53] In blood RT-qPCR (far red dyes), use in resource poor regions. 20 kg, table top device, car alternator/battery or mains capable.
Virocyt [88] Flow based particle detection of virus. Fluorescent staining of both genome and protein. EXPERIMENTAL uses; not suited for clinical
samples due to high levels of other protein.
Lab-on-chip Optoﬂuidic detection [89] LoD 0.2PFU/ml. Ampliﬁcation free by using sample concentration before measurement by laser.
Circulating microRNA [90] Measuring EBOV induced changes in miRNA in humans and NHP. Proof of principle assay. 36 diﬀerentially expressed miRNAs; 93.1%
(27/29) accurate in acute cases
Padlock probe detection [91] Rolling circle ampliﬁcation (RCA) of EBOV L gene on magnetic beads followed by secondary circle to circle ampliﬁcation. Combined
Detection by biotin capture and magnetic bead for an electrochemical and magnetic actuation. LOD:33 cDNA molecules.
One step FRET-PCR [92] Multiplex assay diﬀerentiating between RT-qPCR products by Tm; 6FAM and LCRed 640 probes. Products from diﬀerent ebolavirus
subtypes had both distinct Tm ﬂuorescence and amplicon size which allows typing.
FILODIAG [62] Filovirus Diagnostics. Ultra-fast laser ampliﬁcation using laser-heated, primer coated, nanoparticles for rapid heating/cooling. Aim of
15min sample-to-result.
Moﬁna [63] Portable POC device for the detection of Ebolavirus or Marburg virus. Sample-to-result in 75min
Table 5
RT-LAMP papers, targets, primers and sensitivity for Ebolavirus detection.
Paper Target Primers Sensitivity
Kurosaki [41,42] Trailer EBOV F3 CAATAAACAACTATTTAAATAAC 100% (92.5–100) compared to RT-qPCR
EBOV FIP GTCACACATGCTGCATTGTGTTTTCTATATTTAGCCTCTCTCCCT
EBOV BIP AACGCAACATAATAAACTCTGCATTTTATCAATAACAATATGAGCCCAG








Xu [85] GP EBOV-F3 TGGTTCAAGTGCACAGTCAA LOD: 30 copies (RNA) ≥102 TCID50/ml (Viral particle)
EBOV-B3 TGTCTGCTCTACGGTGATGT




Benzine [44] GP EBOV F3 GACGGGAGTGAGTGTCTACC LOD: 2.8× 102 PFU/reaction (Kikwit) 1× 103 PFU/
reaction (Makona)EBOV B3 AGCTTGGGGCAGTATCAGAA
EBOV FL GCACATACCGGCACC
EBOV BL CTTCCTGTATGATCGACTTGCTTC
EBOV FIP (F1c+ F2) GGCACATGGTCCCGTTCCTGATTTTTTAGCGCCAGACGGGATTCG
EBOV BIP (B1c+B2) TGCCTTCCACAAAGAGGGTGCTTTTTGCGAAAGTCGTTCCTCGGT




SUDV R CTTAAGGATCCATGGATAAACGGGTGAGAGGTTC 256 copies/reaction
BDBV F CTTAAGAATTCTCACCTGTGATGCTGGAGGA
BDBV R CTTAAGGATCCATGGATCCTCGTCCAATCAG
TAFV F1 ACTATAGGGCGAATTCATGGAGAGTCGGGCCCAC 256 copies/reaction
TAFV F2 AAGGCTGCCCTTAGCTCGCTAGCACAACATGGAGAG
TAFV R2 CGACTCTAGAGGATCCTTACTTGTGGTGCTGAAGG 256 copies/reaction
RESTV F CTTAAGAATTCTTACTGATGGTGCTGCAAGTTGC
RESTV R CTTAAGGATCCATGGATCGTGGGACCAGAAG 64 copies/reaction
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